- Home
- ESEA vs ACIU Comparison
ESEA vs ACIU Comparison
Compare ESEA & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESEA
- ACIU
- Stock Information
- Founded
- ESEA 2005
- ACIU 2003
- Country
- ESEA Greece
- ACIU Switzerland
- Employees
- ESEA N/A
- ACIU N/A
- Industry
- ESEA Marine Transportation
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- ESEA Consumer Discretionary
- ACIU Health Care
- Exchange
- ESEA Nasdaq
- ACIU Nasdaq
- Market Cap
- ESEA 235.7M
- ACIU 247.4M
- IPO Year
- ESEA 2006
- ACIU 2016
- Fundamental
- Price
- ESEA $30.48
- ACIU $1.87
- Analyst Decision
- ESEA Buy
- ACIU Strong Buy
- Analyst Count
- ESEA 1
- ACIU 2
- Target Price
- ESEA $53.00
- ACIU $12.00
- AVG Volume (30 Days)
- ESEA 38.5K
- ACIU 192.4K
- Earning Date
- ESEA 05-22-2025
- ACIU 03-13-2025
- Dividend Yield
- ESEA 8.48%
- ACIU N/A
- EPS Growth
- ESEA N/A
- ACIU N/A
- EPS
- ESEA 16.20
- ACIU N/A
- Revenue
- ESEA $212,897,313.00
- ACIU $30,136,397.00
- Revenue This Year
- ESEA $4.65
- ACIU $120.91
- Revenue Next Year
- ESEA $4.36
- ACIU $13.82
- P/E Ratio
- ESEA $1.90
- ACIU N/A
- Revenue Growth
- ESEA 12.43
- ACIU 84.51
- 52 Week Low
- ESEA $28.36
- ACIU $1.87
- 52 Week High
- ESEA $50.92
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- ESEA 40.78
- ACIU 23.14
- Support Level
- ESEA $30.60
- ACIU $1.95
- Resistance Level
- ESEA $31.85
- ACIU $2.05
- Average True Range (ATR)
- ESEA 1.11
- ACIU 0.12
- MACD
- ESEA -0.13
- ACIU -0.02
- Stochastic Oscillator
- ESEA 35.42
- ACIU 0.00
About ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.